We are live on ! Find out more
TYRA icon

Tyra Biosciences

133 hedge funds and large institutions have $1.49B invested in Tyra Biosciences in 2025 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,580% more call options, than puts

Call options by funds: $334K | Put options by funds: $5K

190% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 10

140% more funds holding in top 10

Funds holding in top 10: 512 (+7)

92% more capital invested

Capital invested by funds: $778M → $1.49B (+$716M)

15% more funds holding

Funds holding: 116133 (+17)

13% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 38

2.08% more ownership

Funds ownership: 104.39%106.47% (+2.1%)

Holders
133
Holders Change
+17
Holders Change %
+14.66%
% of All Funds
1.62%
Holding in Top 10
12
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+140%
% of All Funds
0.15%
New
29
Increased
43
Reduced
38
Closed
10
Calls
$334K
Puts
$5K
Net Calls
+$329K
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$321M
NI
2
Nextech Invest
Switzerland
$107M
APMC
3
Alta Partners Management Company
Wyoming
$101M -$4.72M -256,871 -6%
CC
4
Commodore Capital
New York
$88.7M
CPX
5
Canaan Partners XI
California
$88.7M -$4.29M -233,780 -6%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$77.1M +$1.11M +60,638 +2%
TCM
7
TCG Crossover Management
California
$76.2M
VPC
8
Vestal Point Capital
New York
$63.8M
BI
9
BVF Inc
California
$55.9M -$28M -1,522,129 -42%
BlackRock
10
BlackRock
New York
$54.9M +$3.98M +216,949 +12%
FCM
11
Farallon Capital Management
California
$54.3M +$17M +923,000 +81%
Vanguard Group
12
Vanguard Group
Pennsylvania
$41.3M +$966K +52,600 +3%
KCM
13
Kynam Capital Management
New Jersey
$41.1M -$14.1M -765,506 -33%
5VM
14
5AM Venture Management
California
$27.1M +$1.65M +90,000 +10%
CP
15
Caligan Partners
New York
$24.8M +$4.54M +247,432 +36%
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$23M +$10.9M +592,160 +210%
Balyasny Asset Management
17
Balyasny Asset Management
Illinois
$21.5M -$519K -28,259 -3%
State Street
18
State Street
Massachusetts
$19.7M +$5.9M +320,991 +75%
Marshall Wace
19
Marshall Wace
United Kingdom
$18.7M +$2.02M +109,876 +18%
TECP
20
Trails Edge Capital Partners
Georgia
$18.4M +$12.9M +700,000 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$17.3M +$1.11M +60,302 +10%
SCM
22
Sio Capital Management
New York
$13.8M +$203K +11,055 +2%
BCM
23
Boone Capital Management
Georgia
$10.5M +$7.32M +398,482 New
EC
24
Elmind Capital
New York
$9.2M +$6.43M +350,000 New
EP
25
Eversept Partners
New York
$7.32M +$108K +5,858 +2%

TYRA Hedge Fund Activity: Q4 2025 in Review

133 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Tyra Biosciences (TYRA) for Q4 2025, worth a combined $1.49B — up 92% from $778M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new TYRA positions and 10 closed out — a net gain of 19 holders — while 43 added to existing stakes and 38 trimmed.

The largest buyer was Farallon Capital Management, adding an estimated $17M. The largest seller was BVF Inc, cutting an estimated $28M.

  • 133 institutional investors held Tyra Biosciences (TYRA) as of Q4 2025, up from 116 in Q3 2025.
  • Funds reported $1.49B of Tyra Biosciences stock for Q4 2025, up 92% quarter-over-quarter.
  • 29 funds opened new Tyra Biosciences positions in Q4 2025 and 10 closed out, a net change of +19 holders.
  • The largest Tyra Biosciences buyer in Q4 2025 was Farallon Capital Management, an estimated $17M added.
  • The largest Tyra Biosciences seller in Q4 2025 was BVF Inc, an estimated $28M sold.

Based on aggregated 13F filings for Q4 2025.